Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. William Gradishar

Breast Oncology · NU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    MBDr. Marc Braunstein
    Leading Voice

    Dr. Marc Braunstein

    Hematology & Oncology · Myeloma
    NYU Grossman Long Island School of Medicine
    marcb

    Research

    Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia

    2026

    Via J Clin Oncol

    Research

    Hematology-Oncology Fellows' Use of Artificial Intelligence: A Multicenter Educational Practice and Needs Assessment Survey

    2026

    Via J Cancer Educ

    Research

    Association of Food Insecurity with Reduced History of U.S. Cancer Screening Rates

    2026

    Via Cancer Epidemiol Biomarkers Prev

    Research

    Outpatient step-up dosing of teclistamab and talquetamab in relapsed or refractory

    2026

    Via Leuk Res

    Research

    Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

    2025

    Via Nature Medicine

    Research

    Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

    2025

    Via Nature Medicine

    Research

    A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes.

    2025

    Via Blood

    Research

    A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.

    2025

    Via Future Oncology

    Research

    Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma.

    2023

    Via Clinical Cancer Research

    Research

    Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion.

    2023

    Via Transplantation and Cellular Therapy

    Research

    Outcomes of Patients With Hematologic Malignancies Who Received Inpatient Palliative Care Consultation.

    2022

    Via JCO Oncology Practice

    Research

    Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.

    2022

    Via Leukemia

    Research

    Structural variants shape the genomic landscape and clinical outcome of multiple myeloma.

    2022

    Via Blood Cancer Journal

    Research

    Hemoglobin Alpha Chain Variant Zara Associated With Familial Asymptomatic Hypoxemia.

    2022

    Via Journal of Hematology

    Research

    A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.

    2021

    Via Expert Review of Hematology